JNJ 4796)

Request For Quotation
JNJ 4796) Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Email: liming@bio-fount.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com

JNJ 4796) manufacturers

  • JNJ4796
  • JNJ4796 pictures
  • 2026-07-27
  • CAS:2241664-16-2
  • Purity:
  • Supply Ability: 10g
JNJ 4796) Basic information
Product Name:JNJ 4796)
Synonyms:JNJ 4796);JNJ4796 (JNJ-4796;(R)-N-(2-(2-(4-((2-methyl-2H-tetrazol-5-yl)(phenyl)methyl)piperazine-1-carbonyl)pyridin-4-yl)benzo[d]oxazol-5-yl)acetamide;Acetamide, N-[2-[2-[[4-[(R)-(2-methyl-2H-tetrazol-5-yl)phenylmethyl]-1-piperazinyl]carbonyl]-4-pyridinyl]-5-benzoxazolyl]-
CAS:2241664-16-2
MF:C28H27N9O3
MW:537.58
EINECS:
Product Categories:
Mol File:2241664-16-2.mol
JNJ 4796) Structure
JNJ 4796) Chemical Properties
density 1.44±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 100 mg/mL (186.02 mM; Need ultrasonic)
form Solid
pka13.03±0.43(Predicted)
color White to light yellow
Safety Information
MSDS Information
JNJ 4796) Usage And Synthesis
UsesJNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)[1].
in vivo

Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved[1].
Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD90), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1].

Animal Model:Female BALB/cAnNCrl mice intranasally infected with 2 × 25 μL of 25 × LD50 or 1 × LD90 of H1N1 A/Puerto Rico/8/34 dissolved in sterile phosphate buffered saline (D-PBS)[1]
Dosage:50 and 10 mg/kg.
Administration:Oral twice daily for 7 days.
Result:Resulted in 100% survival at day 21 in comparison to the less potent compound JNJ8897.
References[1] van Dongen MJP, et al. A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science. 2019 Mar 8;363(6431). DOI:10.1126/science.aar6221
JNJ 4796) Preparation Products And Raw materials
Tag:JNJ 4796)(2241664-16-2) Related Product Information
HA/HEMAGGLUTININ protein, INFLUENZA B (ACN29380, SF9) HA/Hemagglutinin Protein, H12N1 (ABB88099, sf9, His) HA/HEMAGGLUTININ protein, H1N1 (ACR08536,SF9, HIS) HA/hemagglutinin protein, H1N1 (biotinylated, ACP41953.1, HEK293, his) HA/hemagglutinin protein, H6N2 (AFJ19048, SF9, his) HA/hemagglutinin protein, influenza A H3N2 (HEK293, his)